SVF
Level A· Stronger Clinical EvidenceMeta-analysis

Systematic Review: Allogenic Use of Stromal Vascular Fraction (SVF) and Decellularized Extracellular Matrices (ECM) as Advanced Therapy Medicinal Products (ATMP) in Tissue Regeneration.

Gentile P., Sterodimas A., Pizzicannella J., Dionisi L., De Fazio D., Calabrese C.

Meta-analysis on Knee Osteoarthritis, Osteoarthritis, Diabetic Foot, Cardiovascular Disease, published in Int J Mol Sci (2020) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Int J Mol Sci (2020)
Country
Switzerland
Reported sample size
—
PMID
32679697
DOI
10.3390/ijms21144982

Abstract (original English)

Stromal vascular fraction (SVF) containing adipose stem cells (ASCs) has been used for many years in regenerative plastic surgery for autologous applications, without any focus on their potential allogenic role. Allogenic SVF transplants could be based on the possibility to use decellularized extracellular matrix (ECM) as a scaffold from a donor then re-cellularized by ASCs of the recipient, in order to develop the advanced therapy medicinal products (ATMP) in fully personalized clinical approaches. A systematic review of this field has been realized in accordance with the Preferred Reporting for Items for Systematic Reviews and Meta-Analyses-Protocols (PRISMA-P) guidelines. Multistep research of the PubMed, Embase, MEDLINE, Pre-MEDLINE, PsycINFO, CINAHL, Clinicaltrials.gov, Scopus database, and Cochrane databases has been conducted to identify articles and investigations on human allogenic ASCs transplant for clinical use. Of the 341 articles identified, 313 were initially assessed for eligibility on the basis of the abstract. Of these, only 29 met all the predetermined criteria for inclusion according to the PICOS (patients, intervention, comparator, outcomes, and study design) approach, and 19 have been included in quantitative synthesis (meta-analysis). Ninety-one percent of the studies previously screened (284 papers) were focused on the in vitro results and pre-clinical e

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Adipose TissueAnimalsExtracellular MatrixHumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsRegenerative MedicineTissue EngineeringTissue ScaffoldsTransplantation, Homologous
KneeArm & ElbowAnkle & FootKnee OsteoarthritisOsteoarthritisDiabetic FootCardiovascular Disease
View on PubMedDOI

Related research